Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Paul Senior who wrote (34580)	3/11/2010 2:28:06 AM
From: Paul Senior	Read Replies (1) of 78659

Klarman does it again. How he sees value in some of choices, I guess I'll never understand. All of a sudden it appears that ABT sees great value in one of them: forbes.com "Investors who doubted the stock picks of financier Seth Klarman were kicking themselves on Wednesday after Facet Biotech, 14% of which is owned by Klarman's Baupost Group, agreed to a $450 million cash buyout from Abbott Laboratories. According to the two companies, Abbott Laboratories ( ABT - news - people ) will pay $27 per share, a slim discount after Facet Biotech ( FACT - news - people ) jumped 66.6% to close at $27.01. Facet's stock traded between $5.86 and $18.35 over 52 weeks leading up to Wednesday." finance.yahoo.com I was in as a hanger-on and got a taste. Had no clue though that this forever unprofitable company would be worth so much money to somebody.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next